Hypoparathyroidism - Pipeline Insight, 2022

DelveInsight’s, “Hypoparathyroidism - Pipeline Insight, 2022,” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Hypoparathyroidism pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Hypoparathyroidism Understanding
Hypoparathyroidism: Overview
Hypoparathyroidism is a rare condition in which the parathyroid glands fail to produce sufficient amounts of parathyroid hormone or the parathyroid hormone produced lacks biologic activity. The symptoms of hypoparathyroidism occur due to low levels of calcium in the blood. The severity of the condition can range from mild symptoms such as a tingling or numbness in the fingers, toes or around the lips (paresthesias) to severe muscle cramps and muscle spasms. The muscle symptoms are often called tetany, a condition characterized by uncontrollable twitching and cramping spasms of certain muscles such as those of the hands, feet, legs, and arms. In rare cases, seizures or fits can occur, or the level of consciousness can be depressed.

""Hypoparathyroidism - Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hypoparathyroidism pipeline landscape is provided which includes the disease overview and Hypoparathyroidism treatment guidelines. The assessment part of the report embraces, in depth Hypoparathyroidism commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hypoparathyroidism collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Hypoparathyroidism R&D. The therapies under development are focused on novel approaches to treat/improve Hypoparathyroidism.

Hypoparathyroidism Emerging Drugs Chapters
This segment of the Hypoparathyroidism report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hypoparathyroidism Emerging Drugs
• TransCon PTH: Ascendis Pharma
TransCon™ PTH is an investigational prodrug of parathyroid hormone (PTH) in development as a once-daily hormone replacement therapy. It is designed to restore physiologic levels of PTH 24 hours a day. By doing so, we believe TransCon PTH can address both the short-term symptoms and long-term complications of hypoparathyroidism. The goal is to provide a PTH replacement therapy that normalizes serum and urinary calcium, as well as serum phosphate levels, and improves quality of life. TransCon PTH has orphan designation for the treatment of hypoparathyroidism in both the U.S. and Europe. The company has completed enrollment in the Phase 3 PaTHway Trial of TransCon PTH in adults with hypoparathyroidism, with topline results expected in Q1 2022.

• Encaleret: Calcilytix Therapeutics
Encaleret is an investigational small molecule antagonist of the calcium sensing receptor (CaSR). The CaSR is a G-protein-coupled receptor for which extracellular calcium is the primary ligand. The major physiologic role of the CaSR is to function conceptually as a ‘calciostat’ and maintain serum calcium levels by regulating the release of PTH and calcium reabsorption.
Further product details are provided in the report……..

Hypoparathyroidism: Therapeutic Assessment
This segment of the report provides insights about the different Hypoparathyroidism drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Hypoparathyroidism
There are approx. 8+ key companies which are developing the therapies for Hypoparathyroidism. The companies which have their Hypoparathyroidism drug candidates in the most advanced stage, i.e. phase III include, Ascendis Pharma.

• Phases
DelveInsight’s report covers around 8+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Hypoparathyroidism pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hypoparathyroidism: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hypoparathyroidism therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hypoparathyroidism drugs.

Hypoparathyroidism Report Insights
• Hypoparathyroidism Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Hypoparathyroidism Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Hypoparathyroidism drugs?
• How many Hypoparathyroidism drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hypoparathyroidism?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hypoparathyroidism therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Hypoparathyroidism and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• Ascendis Pharma
• Calcilytix Therapeutics
• Amolyt Pharma
• AEterna Zentaris Inc
• Chugai Pharmaceutical
• Entera Bio
• Sigilon Therapeutics
• ProLynx
• Extend Biosciences

Key Products
• TransCon PTH
• Encaleret
• AZP 3601
• PCO 371
• EB612
• EXT607
• PTH(1-34)
• AEZS 150

Companies

• Ascendis Pharma
• Calcilytix Therapeutics
• Amolyt Pharma
• AEterna Zentaris Inc
• Chugai Pharmaceutical
• Entera Bio
• Sigilon Therapeutics
• ProLynx
• Extend Biosciences